Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?

Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Trenor AM

Circulation1 Jun 1988Cited by 60 (Europe PMC)

PMID3286039DOI10.1161/01.cir.77.6.1319PepBankPUB-03286039

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In bypass patients, total blood loss per square meter over the first 72 hr did not differ significantly: DDAVP 458 +/- 206 ml versus placebo 536 +/- 304 ml.
In plain wordsIn bypass patients, DDAVP did not significantly change total blood loss compared with placebo.
Peptide
Desmopressin
Outcome
No significant changeTotal blood loss per square meter
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
Total blood loss per square meter, mean
458 ml
DDAVP group, first 72 hr
Total blood loss per square meter, SD
206 ml
DDAVP group, first 72 hr
Total blood loss per square meter, mean
536 ml
placebo group, first 72 hr
Total blood loss per square meter, SD
304 ml
placebo group, first 72 hr
Source sentences
Summary
Results showed no significant differences either in total blood loss per square meter (458 +/- 206 ml in the DDAVP group vs 536 +/- 304 ml in the placebo group) or in necessity for red cell transfusions (1642 +/- 705 ml in the DDAVP group vs 1574 +/- 645 ml in the placebo group) in the first 72 hr after surgery.
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603901
02HumanRandomized controlled trialEfficacy outcome
In bypass patients, red cell transfusions over the first 72 hr did not differ significantly: DDAVP 1642 +/- 705 ml versus placebo 1574 +/- 645 ml.
In plain wordsIn bypass patients, red cell transfusions did not differ significantly between DDAVP and placebo.
Peptide
Desmopressin
Outcome
No significant changeRed cell transfusions
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
Red cell transfusion volume, mean
1642 ml
DDAVP group, first 72 hr
Red cell transfusion volume, SD
705 ml
DDAVP group, first 72 hr
Red cell transfusion volume, mean
1574 ml
placebo group, first 72 hr
Red cell transfusion volume, SD
645 ml
placebo group, first 72 hr
Source sentences
Summary
Results showed no significant differences either in total blood loss per square meter (458 +/- 206 ml in the DDAVP group vs 536 +/- 304 ml in the placebo group) or in necessity for red cell transfusions (1642 +/- 705 ml in the DDAVP group vs 1574 +/- 645 ml in the placebo group) in the first 72 hr after surgery.
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603902
03HumanRandomized controlled trialEfficacy outcome
In bypass patients, intraoperative blood loss per square meter was lower with DDAVP (131 +/- 106 ml) than placebo (193 +/- 137 ml, p less than .02).
In plain wordsIn bypass patients, DDAVP reduced intraoperative blood loss compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseIntraoperative blood loss per square meter
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Measurements
Intraoperative blood loss per square meter, mean
131 ml
DDAVP group
Intraoperative blood loss per square meter, SD
106 ml
DDAVP group
Intraoperative blood loss per square meter, mean
193 ml
placebo group
Intraoperative blood loss per square meter, SD
137 ml
placebo group
Source sentences
Summary
Only intraoperative blood loss per square meter was significantly lower (p less than .02) in the DDAVP group (131 +/- 106 ml) as compared with the placebo group (193 +/- 137 ml).
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603903
04HumanRandomized controlled trialEfficacy outcome
In bypass patients, bleeding time prolongation at 90 min was lower with DDAVP than placebo (p less than .001).
In plain wordsIn bypass patients, DDAVP reduced bleeding time prolongation compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseBleeding time prolongation
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Source sentences
Summary
The prolongation of bleeding time and the decrease of factor VIII:C and factor VIII:von Willebrand factor 90 min after treatment were significantly lower (p less than .001) in the DDAVP group as compared with the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603904
05HumanRandomized controlled trialMechanism
In bypass patients, the factor VIII:C decrease at 90 min was lower with DDAVP than placebo (p less than .001).
In plain wordsIn bypass patients, DDAVP reduced the fall in factor VIII:C compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseFactor VIII:C decrease
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Source sentences
Summary
The prolongation of bleeding time and the decrease of factor VIII:C and factor VIII:von Willebrand factor 90 min after treatment were significantly lower (p less than .001) in the DDAVP group as compared with the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603905
06HumanRandomized controlled trialMechanism
In bypass patients, the factor VIII:von Willebrand factor decrease at 90 min was lower with DDAVP than placebo (p less than .001).
In plain wordsIn bypass patients, DDAVP reduced the fall in factor VIII:von Willebrand factor compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseFactor VIII:von Willebrand factor decrease
Study
n = 100
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 micrograms/kgAs given in this study (human).
Source sentences
Summary
The prolongation of bleeding time and the decrease of factor VIII:C and factor VIII:von Willebrand factor 90 min after treatment were significantly lower (p less than .001) in the DDAVP group as compared with the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
We have investigated the effect of DDAVP administration in a double-blind, randomized, prospective trial including 100 patients placed on cardiopulmonary bypass during surgery.
Summary · context
Fifty patients received 0.3 micrograms/kg DDAVP and 50 patients received a placebo administered in a 50 ml saline solution over 15 min when cardiopulmonary bypass had been concluded.
Report a problemFND-0328603906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.